[1]
|
Shih, I., Wang, Y. and Wang, T. (2021) The Origin of Ovarian Cancer Species and Precancerous Landscape. The American Journal of Pathology, 191, 26-39. https://doi.org/10.1016/j.ajpath.2020.09.006
|
[2]
|
Richardson, D.L., Eskander, R.N. and O’Malley, D.M. (2023) Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance. JAMA Oncology, 9, Article No. 851. https://doi.org/10.1001/jamaoncol.2023.0197
|
[3]
|
Avesani, G., Arshad, M., Lu, H., Fotopoulou, C., Cannone, F., Melotti, R., et al. (2020) Radiological Assessment of Peritoneal Cancer Index on Preoperative CT in Ovarian Cancer Is Related to Surgical Outcome and Survival. La Radiologia Medica, 125, 770-776. https://doi.org/10.1007/s11547-020-01170-6
|
[4]
|
Griffiths, C.T. (1975) Surgical Resection of Tumor Bulk in the Primary Treatment of Ovarian Carcinoma. National Cancer Institute Monographs, 42, 101-104.
|
[5]
|
Shi, Y., Dai, M., Zhang, Y., Qi, Y., Li, Z. and Cai, H. (2021) Residual Tumor Diameter Predicts Progression after Primary Debulking Surgery of Ovarian Clear Cell Carcinoma (OCCC): Clinicopathologic Study of Stage II-IV OCCC Patients from a Single Institution. Cancer Management and Research, 13, 2215-2222. https://doi.org/10.2147/cmar.s293677
|
[6]
|
Kahn, R.M., McMinn, E., Yeoshoua, E., Boerner, T., Zhou, Q., Iasonos, A., et al. (2023) Intrathoracic Surgery as Part of Primary Cytoreduction for Advanced Ovarian Cancer: Going to the Next Level—A Memorial Sloan Kettering Cancer Center Study. Gynecologic Oncology, 170, 46-53. https://doi.org/10.1016/j.ygyno.2022.12.023
|
[7]
|
Coada, C.A., Dondi, G., Ravegnini, G., Di Costanzo, S., Tesei, M., Fiuzzi, E., et al. (2023) Optimal Number of Neoadjuvant Chemotherapy Cycles Prior to Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis of Progression-Free Survival and Overall Survival. Journal of Gynecologic Oncology, 34, e82. https://doi.org/10.3802/jgo.2023.34.e82
|
[8]
|
Revaux, A., Carbonnel, M., Kanso, F., Naoura, I., Asmar, J., Kadhel, P., et al. (2020) Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: An Update. Hormone Molecular Biology and Clinical Investigation, 41, Article ID: 20190028. https://doi.org/10.1515/hmbci-2019-0028
|
[9]
|
Holcomb, K., Vucetic, Z., Miller, M.C. and Knapp, R.C. (2011) Human Epididymis Protein 4 Offers Superior Specificity in the Differentiation of Benign and Malignant Adnexal Masses in Premenopausal Women. American Journal of Obstetrics and Gynecology, 205, 358.e1-358.e6. https://doi.org/10.1016/j.ajog.2011.05.017
|
[10]
|
Luo, C., Zhao, M., Chen, X., Shahabi, S., Qiang, W., Zeng, L., et al. (2018) HE4 and Eif3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction. Journal of Cancer, 9, 2472-2479. https://doi.org/10.7150/jca.25184
|
[11]
|
Saffarieh, E., Nassiri, S. and Mirmohammadkhani, M. (2022) Predicting Value of HE4 and CA125 Markers for Optimal Cytoreductive Surgery in Ovarian Cancer Patients. European Journal of Translational Myology, 32, Article No. 10671. https://doi.org/10.4081/ejtm.2022.10671
|
[12]
|
Szender, J.B., Emmons, T., Belliotti, S., Dickson, D., Khan, A., Morrell, K., et al. (2017) Impact of Ascites Volume on Clinical Outcomes in Ovarian Cancer: A Cohort Study. Gynecologic Oncology, 146, 491-497. https://doi.org/10.1016/j.ygyno.2017.06.008
|
[13]
|
Iyoshi, S., Kimura, M., Yoshihara, M., Kunishima, A., Miyamoto, E., Fujimoto, H., et al. (2024) Detailed Analysis of the Histology-Specific Impact of Ascites Volume on the Outcome of Epithelial Ovarian Cancer: A Multi-Institutional Retrospective Cohort Study. BMC Cancer, 24, Article No. 1479. https://doi.org/10.1186/s12885-024-13218-1
|
[14]
|
Janco, J.M.T., Glaser, G., Kim, B., McGree, M.E., Weaver, A.L., Cliby, W.A., et al. (2015) Development of a Prediction Model for Residual Disease in Newly Diagnosed Advanced Ovarian Cancer. Gynecologic Oncology, 138, 70-77. https://doi.org/10.1016/j.ygyno.2015.04.013
|
[15]
|
Ayhan, A., Gultekin, M., Taskiran, C., Dursun, P., Firat, P., Bozdag, G., et al. (2007) Ascites and Epithelial Ovarian Cancers: A Reappraisal with Respect to Different Aspects. International Journal of Gynecological Cancer, 17, 68-75. https://doi.org/10.1111/j.1525-1438.2006.00777.x
|
[16]
|
Ethier, J., Desautels, D.N., Templeton, A.J., Oza, A., Amir, E. and Lheureux, S. (2017) Is the Neutrophil-to-Lymphocyte Ratio Prognostic of Survival Outcomes in Gynecologic Cancers? A Systematic Review and Meta-Analysis. Gynecologic Oncology, 145, 584-594. https://doi.org/10.1016/j.ygyno.2017.02.026
|
[17]
|
Plaja, A., Teruel, I., Ochoa-de-Olza, M., Cucurull, M., Arroyo, Á.J., Pardo, B., et al. (2023) Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery. International Journal of Molecular Sciences, 24, Article No. 11420. https://doi.org/10.3390/ijms241411420
|
[18]
|
Miao, Y., Yan, Q., Li, S., Li, B. and Feng, Y. (2016) Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Are Predictive of Chemotherapeutic Response and Prognosis in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy. Cancer Biomarkers, 17, 33-40. https://doi.org/10.3233/cbm-160614
|
[19]
|
Marchetti, C., D’Indinosante, M., Bottoni, C., Di Ilio, C., Di Berardino, S., Costantini, B., et al. (2021) NLR and BRCA Mutational Status in Patients with High Grade Serous Advanced Ovarian Cancer. Scientific Reports, 11, Article No. 11125. https://doi.org/10.1038/s41598-021-90361-w
|
[20]
|
Van Nguyen, J.M., Ferguson, S.E., Bernardini, M.Q., May, T., Laframboise, S., Hogen, L., et al. (2020) Preoperative Neutrophil-to-Lymphocyte Ratio Predicts 30 Day Postoperative Morbidity and Survival after Primary Surgery for Ovarian Cancer. International Journal of Gynecological Cancer, 30, 1378-1383. https://doi.org/10.1136/ijgc-2020-001378
|
[21]
|
Meyer, L.A., Cronin, A.M., Sun, C.C., Bixel, K., Bookman, M.A., Cristea, M.C., et al. (2016) Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. Journal of Clinical Oncology, 34, 3854-3863. https://doi.org/10.1200/jco.2016.68.1239
|
[22]
|
Fagotti, A., Ferrandina, G., Vizzielli, G., Fanfani, F., Gallotta, V., Chiantera, V., et al. (2016) Phase III Randomised Clinical Trial Comparing Primary Surgery versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer with High Tumour Load (SCORPION Trial): Final Analysis of Peri-Operative Outcome. European Journal of Cancer, 59, 22-33. https://doi.org/10.1016/j.ejca.2016.01.017
|
[23]
|
Machida, H., Tokunaga, H., Matsuo, K., Matsumura, N., Kobayashi, Y., Tabata, T., et al. (2020) Survival Outcome and Perioperative Complication Related to Neoadjuvant Chemotherapy with Carboplatin and Paclitaxel for Advanced Ovarian Cancer: A Systematic Review and Meta-Analysis. European Journal of Surgical Oncology, 46, 868-875. https://doi.org/10.1016/j.ejso.2019.11.520
|
[24]
|
Vergote, I., Tropé, C.G., Amant, F., Kristensen, G.B., Ehlen, T., Johnson, N., et al. (2010) Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. New England Journal of Medicine, 363, 943-953. https://doi.org/10.1056/nejmoa0908806
|
[25]
|
da Costa, A.A.B.A., Valadares, C.V., Baiocchi, G., Mantoan, H., Saito, A., Sanches, S., et al. (2015) Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer. Annals of Surgical Oncology, 22, 971-978. https://doi.org/10.1245/s10434-015-4623-z
|